CorWave, a medical technology company that develops innovative mechanical circulatory support devices, has announced that it has completed a $17.1 million (€15.5M) Series B financing. Existing share...
Read more“STAT-Diagnostica has an exciting technology that could significantly advance the diagnosis and triage of infectious diseases. We are impressed with the team and look forward to working with them in...
Read moreAura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it secured an add...
Read moreStudy shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models
Read moreCVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completi...
Read moreMIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...
Read moreLed by new investor Gilde Healthcare , the financing round al so drew participation from existing investors , including Kurma Partners ; Ysios Capital ; Idinvest Partners ; Boehringer Ingelheim Ventur...
Read moreYsios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...
Read moreFinancing will advance Sanifit’s lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and through phase II/III for calciphylaxis
Read morePfizer has made an upfront payment of $87.5 million for the minority equity interest and exclusive option, with additional potential payments of up to $512.5 million upon option exercise and potential...
Read moreÉsta es la segunda inversión de Ysios Capital a través de su segundo fondo, Ysios BioFund II Innvierte, que estará abierto a nuevos inversores hasta septiembre de 2015
Read moreÉsta es la primera inversión de Ysios Capital a través de su segundo fondo, Ysios BioFund II Innvierte, que estará abierto a nuevos inversores hasta septiembre de 2015
Read more